We always think of our customers with an open mind
Press Release
NTL Healthcare Participated in ‘KIMES 2022’ and Has Successfully Completed the Promotion of ‘CerviCARE®'
Author
엔티엘헬스케어
Date
2023-05-31 11:48
Views
207
NTL Healthcare Participated in ‘KIMES 2022’ and Has Successfully Completed the Promotion of ‘CerviCARE®'.
NTL Healthcare (CEO Tae-hee Kim) announced on the 18th that it participated in the "Korea International Medical & Hospital Equipment Show (KIMES 2022)," which was held from the 10th to the 14th at COEX in Samsung-dong, Seoul, and showed its ▲CerviCARE®, cervical and women's disease integrated screening platform, and ▲Dr.Cervicam C20, cervical magnification imaging and reading device.
'CerviCARE®' of NTL Healthcare is a cervical and women's disease diagnosis platform that incorporates medical expertise accumulated over 27 years. At this event, NTL demonstrated the cervical cancer artificial intelligence (AI) image analysis system.
'CerviCARE® AI' is a cervical cancer image diagnosis software that assists medical professionals in their decision-making during cervical cancer screening. Based on cervical images big data, it can distinguish between normal (negative) and abnormal (positive) cervical images and further classify normal images into normal and atypical images. Additionally, it can classify and show cervical morphological abnormalities, assisting medical professionals in determining the direction of further treatment.
NTL’s software and hardware integrated solution for cervical cancer screening, the world's only one, has received international attention for its outstanding technology.
Tae-hee Kim, CEO of NTL Healthcare, said, "We will develop 'CerviCARE®', a cervical diagnostic platform that considers the convenience of medical professionals, into a women's disease diagnostic platform, and provide even higher quality medical services." She added, "CerviCARE® AI is receiving even more attention in overseas markets where remote medical services are becoming more prevalent. It can be easily used in medically underdeveloped regions, such as Africa, where the incidence of cervical cancer is high, and we hope that it will bring about a revolutionary change in improving the quality of life for women around the world."
Meanwhile, NTL Healthcare, a company that introduced cervical magnification imaging and reading system in Korea in 1996, provides various screening services including cancer screening for women and continues to develop and supply new products that can improve women's health.
NTL Healthcare (CEO Tae-hee Kim) announced on the 18th that it participated in the "Korea International Medical & Hospital Equipment Show (KIMES 2022)," which was held from the 10th to the 14th at COEX in Samsung-dong, Seoul, and showed its ▲CerviCARE®, cervical and women's disease integrated screening platform, and ▲Dr.Cervicam C20, cervical magnification imaging and reading device.
'CerviCARE®' of NTL Healthcare is a cervical and women's disease diagnosis platform that incorporates medical expertise accumulated over 27 years. At this event, NTL demonstrated the cervical cancer artificial intelligence (AI) image analysis system.
'CerviCARE® AI' is a cervical cancer image diagnosis software that assists medical professionals in their decision-making during cervical cancer screening. Based on cervical images big data, it can distinguish between normal (negative) and abnormal (positive) cervical images and further classify normal images into normal and atypical images. Additionally, it can classify and show cervical morphological abnormalities, assisting medical professionals in determining the direction of further treatment.
NTL’s software and hardware integrated solution for cervical cancer screening, the world's only one, has received international attention for its outstanding technology.
Tae-hee Kim, CEO of NTL Healthcare, said, "We will develop 'CerviCARE®', a cervical diagnostic platform that considers the convenience of medical professionals, into a women's disease diagnostic platform, and provide even higher quality medical services." She added, "CerviCARE® AI is receiving even more attention in overseas markets where remote medical services are becoming more prevalent. It can be easily used in medically underdeveloped regions, such as Africa, where the incidence of cervical cancer is high, and we hope that it will bring about a revolutionary change in improving the quality of life for women around the world."
Meanwhile, NTL Healthcare, a company that introduced cervical magnification imaging and reading system in Korea in 1996, provides various screening services including cancer screening for women and continues to develop and supply new products that can improve women's health.
